Celgene Co. (CELG) Stake Decreased by SevenBridge Financial Group LLC
SevenBridge Financial Group LLC lessened its holdings in shares of Celgene Co. (NASDAQ:CELG) by 54.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 612 shares of the biopharmaceutical company’s stock after selling 737 shares during the period. SevenBridge Financial Group LLC’s holdings in Celgene were worth $39,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently made changes to their positions in CELG. Bruderman Asset Management LLC bought a new position in shares of Celgene in the fourth quarter valued at $25,000. Murphy Pohlad Asset Management LLC bought a new position in shares of Celgene in the fourth quarter valued at $25,000. Athena Capital Advisors LLC bought a new position in shares of Celgene in the fourth quarter valued at $27,000. Berman Capital Advisors LLC bought a new position in shares of Celgene in the fourth quarter valued at $32,000. Finally, Doyle Wealth Management bought a new position in shares of Celgene in the fourth quarter valued at $44,000. 74.19% of the stock is currently owned by hedge funds and other institutional investors.
NASDAQ CELG opened at $88.46 on Friday. Celgene Co. has a twelve month low of $58.59 and a twelve month high of $95.30. The company has a debt-to-equity ratio of 3.21, a quick ratio of 2.12 and a current ratio of 2.23. The company has a market cap of $62.13 billion, a price-to-earnings ratio of 11.62, a PEG ratio of 0.39 and a beta of 1.69.
In related news, Director Ernest Mario purchased 2,000 shares of the stock in a transaction dated Tuesday, February 12th. The shares were acquired at an average cost of $89.99 per share, for a total transaction of $179,980.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director James J. Loughlin sold 23,466 shares of the business’s stock in a transaction on Thursday, February 7th. The shares were sold at an average price of $87.29, for a total transaction of $2,048,347.14. Following the transaction, the director now owns 62,102 shares in the company, valued at $5,420,883.58. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.
Several research analysts have issued reports on CELG shares. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $100.00 price target on shares of Celgene in a report on Thursday, January 3rd. reaffirmed a “buy” rating on shares of Celgene in a report on Monday, December 3rd. William Blair reaffirmed a “buy” rating on shares of Celgene in a report on Thursday, February 28th. Morgan Stanley dropped their price target on Celgene from $93.00 to $88.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 19th. Finally, Canaccord Genuity cut Celgene from a “buy” rating to a “hold” rating in a report on Thursday, January 3rd. Two research analysts have rated the stock with a sell rating, eleven have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $100.94.
ILLEGAL ACTIVITY WARNING: “Celgene Co. (CELG) Stake Decreased by SevenBridge Financial Group LLC” was originally published by Daily Political and is owned by of Daily Political. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.dailypolitical.com/2019/03/16/celgene-co-celg-stake-decreased-by-sevenbridge-financial-group-llc.html.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
Featured Article: Growth Stocks
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.